.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,508,269

« Back to Dashboard

Claims for Patent: 5,508,269

Title: Aminoglycoside formulation for aerosolization
Abstract:An aminoglycoside formulation for delivery by aerosolization. The concentrated aminoglycoside formulation containing an efficacious amount of aminoglycoside able to inhibit 95-100% of susceptible bacteria. Aminoglycoside formulated in 5 ml solution of a quarter normal saline having pH between 5.5 and 6.5. The method for treatment of endobronchial infections by a produced by a formulation delivered as an aerosol having mass medium average diameter predominantly between 1 to 5 .mu., produced by a jet or ultrasonic nebulizer.
Inventor(s): Smith; Arnold L. (Columbia, MO), Ramsey; Bonnie W. (Seattle, WA), Montgomery; Alan B. (Bellevue, WA)
Assignee: Pathogenesis Corporation (Seattle, WA)
Application Number:08/325,705
Patent Claims: 1. An aerosol formulation for suppression and inhibition of at least 95% of susceptible bacteria in endobronchial space of a patient suffering from the endobronchial infection,

said formulation comprising from about 200 mg to about 400 of aminoglycoside dissolved in about 5 ml of solution containing about 0.225% of sodium chloride;

said formulation having pH between about 5.5 and 6.5;

said formulation administered by aerosolization using a jet or ultrasonic nebulizer able to produce predominantly aerosol particle size between 1 and 5 .mu..

2. The aerosol of claim 1 wherein the pH is 6.0.

3. The aerosol of claim 2 wherein the nebulizer is jet nebulizer.

4. The aerosol of claim 2 wherein the nebulizer is ultrasonic nebulizer.

5. An aerosol formulation for suppression and inhibition of at least 95% of Pseudomonas aeruginosa bacteria in endobronchial space of a patient suffering from the Pseudomonas aeruginosa infection,

said formulation comprising about 300 mg of tobramycin dissolved in about 5 ml of solution containing 0.225% of sodium chloride;

said formulation having Ph between about 5.5 and 6.5;

said formulation administered by aerosolization using a jet or ultrasonic nebulizer able to produce predominantly aerosol particle size between 1 and 5 .mu..

6. The aerosol of claim 5 wherein the Ph is 6.0.

7. The aerosol of claim 6 wherein the nebulizer is jet nebulizer.

8. The aerosol of claim 6 wherein the nebulizer is ultrasonic nebulizer.

9. A method for treatment of Pseudomonas aeruginosa bacteria end bronchial infections by providing patient in need of such treatment an aerosol formulation comprising about 300 mg of tobramycin dissolved in about 5 ml of solution containing 0.225% of sodium chloride;

said formulation having pH between about 5.5 and 6.5;

said formulation administered by aerosolization using a jet or ultrasonic nebulizer able to produce predominantly aerosol particle size between 1 and 5 .mu..

10. The method of claim 9 wherein the pH of the aerosol formulation is about 6.0.

11. The method of claim 10 wherein the nebulizer used for administration of the aerosol formulation is the jet nebulizer.

12. The method of claim 10 wherein the nebulizer used for administration of the aerosol formulation is the ultrasonic nebulizer.

13. A method for treatment of Pseudomonas aeruginosa bacteria endobronchial infections by providing patient in need of such treatment an aerosol formulation comprising about 200 to about 400 mg of aminoglycoside dissolved in about 5 ml of solution containing 0.225% of sodium chloride;

said formulation having pH between about 5.5 and 6.5;

said formulation administered by aerosolization using a jet or ultrasonic nebulizer able to produce predominantly aerosol particle size between 1 and 5 .mu..

14. The method of claim 13 wherein the pH of the aerosol formulation is about 6.0.

15. The method of claim 14 wherein the nebulizer used for administration of the aerosol formulation is the jet nebulizer.

16. The method of claim 14 wherein the nebulizer used for administration of the aerosol formulation is the ultrasonic nebulizer.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc